Abstracts tagged "Disease Activity and clinical trials"

Abstract Number: 2513 • 2019 ACR/ARP Annual Meeting
Relationships Between Psoriatic Arthritis Disease Activity Score and Patient-Reported Outcomes in Patients with Psoriatic Arthritis: Post Hoc Analysis of Two Phase 3 Studies
Laura Coates¹, Andrew Bushmakin ², Oliver FitzGerald ³, Dafna Gladman ⁴, Lara Fallon ⁵, Joseph Cappelleri ², Ming-Ann Hsu ⁶ and Philip Helliwell ⁷, ¹University of Oxford, Oxford, United Kingdom, ²Pfizer Inc, Groton, CT, ³University College Dublin, Dublin, Ireland, ⁴University of Toronto, Toronto, ON, Canada, ⁵Pfizer Inc, Montreal, QC, Canada, ⁶Pfizer Inc, Collegeville, PA, ⁷University of Leeds, Leeds, United Kingdom
Background/Purpose: Psoriatic arthritis (PsA) is a complex heterogeneous disease associated with multiple domains. Psoriatic Arthritis Disease Activity Score (PASDAS) is a composite disease activity measure…
Abstract Number: 2514 • 2019 ACR/ARP Annual Meeting
Relationships Between Minimal Disease Activity and Patient-Reported Outcomes in Patients with Psoriatic Arthritis: Post Hoc Analysis of Two Phase 3 Studies
Philip Helliwell¹, Andrew Bushmakin ², Dafna Gladman ³, Oliver FitzGerald ⁴, Lara Fallon ⁵, Joseph Cappelleri ², Ming-Ann Hsu ⁶ and Laura Coates ⁷, ¹University of Leeds, Leeds, United Kingdom, ²Pfizer Inc, Groton, CT, ³University of Toronto, Toronto, ON, Canada, ⁴University College Dublin, Dublin, Ireland, ⁵Pfizer Inc, Montreal, QC, Canada, ⁶Pfizer Inc, Collegeville, PA, ⁷University of Oxford, Oxford, United Kingdom
Background/Purpose: PsA is associated with multiple disease domains, requiring the use of different clinical measures and patient-reported outcomes (PROs) to assess improvements in disease activity…
Abstract Number: 2548 • 2019 ACR/ARP Annual Meeting
Abatacept Failed to Demonstrate Efficacy in an SLE Trial with Low Placebo Response Rates, Although Global Assessments Indicated Less Flare Severity
Aikaterini Thanou¹, Cristina Arriens ², Teresa Aberle ¹, Heather Miller ¹, Lydia Mitchell ³, Stan Kamp ¹, Anca Askanase ⁴, Stavros Stavrakis ⁵, Judith James ² and Joan T. Merrill ⁶, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, ⁴Columbia University, New York, ⁵University of Oklahoma Health Sciences Center, Oklahoma City, ⁶Okalahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Abatacept (ABA) is a fusion protein of the extracellular domain of CTLA4 and human IgG1-Fc, constructed to inhibit B/T cell co-stimulation. Previous studies of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].